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ABSTRACT
Eighty percent of the global 17 million deaths due to cardiovascular disease (CVD) 
occur in low and middle income countries (LMICs). The burden of CVD and other 
noncommunicable diseases (NCDs) is expected to markedly increase because of 
the global aging of the population and increasing exposure to detrimental lifestyle-
related risk in LMICs. Interventions to reduce four main risks related to modifiable 
behaviors (tobacco use, unhealthy diet, low physical activity and excess alcohol 
consumption) are key elements for effective primary prevention of the four main 
NCDs (CVD, cancer, diabetes and chronic pulmonary disease). These behaviors are 
best  improved  through  structural  interventions  (e.g.,  clean  air  policy,  taxes  on 
cigarettes, new recipes for processed foods with reduced salt and fat, urban shaping 
to improve mobility, etc.). In addition, health systems in LMICs should be reoriented 
to deliver integrated cost-effective treatment to persons at high risk at the primary 
health care level. The full implementation of a small number of highly cost effective, 
affordable and scalable interventions (“best buys”) is likely to be the necessary and 
sufficient ingredient for curbing NCDs in LMICs. NCDs are both a cause and a 
consequence of poverty. It is therefore important to frame NCD prevention and 
control within the broader context of social determinants and development agenda. 
The  recent  emphasis  on  NCDs  at  a  number  of  health  and  economic  forums 
(including the September 2011 High Level Meeting on NCDs at the United Nations) 
provides a new opportunity to move the NCD agenda forward in LMICs.
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INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of death with 17 million 
deaths worldwide from a total of 57 million annually1 and 80 percent of all 
CVD deaths now occur in low and middle income countries (LMIC). While 
the CVD epidemic is receding in high income countries, CVD mortality 
rates tend to be higher in many LMICs (e.g., up to 300-600 CVD deaths per 
100,000 population) than in Western countries1 and the burden is expected 
to  increase  further  (Figure  1).  We  focus  in  this  paper  on  the  main 
noncommunicable  diseases  (NCD)  (i.e.,  CVD,  cancers,  diabetes,  and 
chronic respiratory diseases1,2). These four diseases contribute to the largest 
share of all deaths worldwide (Figure 1) and they are largely attributable to 
four common preventable risk factors (tobacco, unhealthy diet, excessive 
alcohol use and physical inactivity).1-5 The focus on these NCDs does not 
diminish the need to also address other chronic diseases and conditions that 
are major contributors to the disease burden globally or in certain countries 
(e.g., mental health, violence, car accidents, hemoglobinopathies, rheumatic 
heart diseases, liver diseases, etc).
Fig. 1. Projected deaths by cause for high-, middle- and low-income countries.
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For the sake of simplicity, and consistent with many current documents 
on global health,1-5 we categorize countries according to their gross national 
income (GNI) per capita: less than USD $1,005 for low income countries 
(LIC), USD $1006-3975 for lower middle income countries, USD $3976-
12,275 for upper middle income countries, and USD $12,276 and greater 
for high income countries (HIC).6 Admittedly, development status, social 
conditions,  physical  environments  and  disease  patterns  can  differ  con-
siderably both between and within GNI categories, which underlie that 
health related priorities may vary largely between particular countries.
In this paper we argue that NCDs constitute a major global public health 
crisis with critical challenges to both national health systems and policy 
development.7 Although resources allocated to NCDs is still low in most 
LMICs, the good news is that the epidemic of NCDs in the LMICs is now 
better quantified and visible and that several recent major developments 
have taken place in the international scene to spearhead and accelerate 
improved public health responses at the global and national levels.
THE MOUNTING BURDEN OF CVD AND CHRONIC DISEASES IN 
LMICs
The increasing burden of NCDs in LMICs is predicted by the epidemiologic 
transition theory (e.g., Omran 1971, reprinted in 20058). The epidemiological 
transition posits that disease patterns change along with socio-economic 
development  (Figure  2),  as  a  result  of  improved  control  of  infectious 
diseases,  aging  of  the  populations,  and  globalization  of  risks  such  as 
tobacco use, unhealthy diet, and sedentary habits. In the last stage of the 
epidemiologic transition, which typically prevails in Western countries, 
CVD recedes as a result of improved diet, healthier lifestyles and more 
effective treatment among large segments of the population.9
It is difficult to get reliable data on CVD morbidity and mortality in 
LMICs because of the lack of vital statistics and other adequate systems to 
register  causes  of  deaths  in  the  entire  population  in  most  LMICs. 
Furthermore, the ascertainment of causes of deaths remains a technical 
challenge  in  LMICs  where  such  data  are  available.10  Therefore,  the 
emphasis is on surveillance of CVD risk factors at the population level. The 
focus on risk factors is adequate because current levels of risk factors 
predict  future  trends  of  CVD  events,  while  current  CVD  morbidity  or 
mortality data tend to reflect past levels of risk factors. Reliable information 
on risk factors requires population-based surveys repeated regularly over 
time. The World Health Organization (WHO) has developed standardized 400 PublicHealthReviews,Vol.33,No2
survey instruments for surveys of risk factors in adults (STEPwise approach 
to serveillance - STEPS*), and in children (Global School-based Student 
Health  Survey  - GSHS**).  Surveillance  data  are  necessary  to  guide 
programs and policy at the national level11 and for comparison of risk 
factors between countries and regions.12 Strengthening health information 
systems is therefore a priority for the prevention and control of NCDs in 
LMICs.
Fig. 2. Decreasing mortality rates and changing patterns of causes of deaths along 
stages of the epidemiologic transition.
The global epidemiological situation of CVD risk factors has been 
quantified recently based on a pooled analysis of all available data from 
published and non published population-based surveys.13-16 Based on these 
data and modeling techniques, estimates of CVD risk factor levels can be 
obtained for all countries.***  The prevalence of overweight and diabetes are 
increasing in all countries including in LMICs. Blood pressure and blood 
cholesterol are decreasing in high income countries, but increasing in many 
(but not all) LMICs.17 Other sources of data show that the prevalence of 
    * http://www.who.int/chp/steps/en/ (Accessed 20 May, 2012)
  ** http://www.who.int/chp/gshs/en/ (Accessed 20 May, 2012)
*** http://www.who.int/gho/ncd/en/index.html and http://www.who.int/gho/ncd/risk_factors/
overweight/en/index.html (Accessed 20 May, 2012)CardiovascularDiseaseandGlobalPublicHealth 401
tobacco use is decreasing in high income countries but increasing in most 
LMICs (but not all), which echoes better tobacco control policy in the 
former than the latter.
The demographic transition (i.e., the postponement of age at death) is 
and will remain the main driver of the increasing burden of CVD and other 
NCDs in LMICs during the next few decades,18 as shown in Figure 3. 
Because the likelihood to develop CVD and other NCDs increase strongly 
with age, the number of persons with NCD will inevitably increase along 
with the increasing and aging populations in LMICs. It is therefore a great 
challenge to oppose this large increase in NCDs, attributable to demographic 
pressure, with prevention strategies that aim to reduce risk factors of CVD 
in  the  population.  This  observation  should  remind  us  to  avoid  setting 
unrealistic goals for prevention programs and to plan increasing health care 
resources for CVD management during the next few decades (e.g., training 
of health professionals, hospital beds for CVD, equipment, medications, 
etc.).
Fig. 3. Decomposition of projected change in numbers of chronic disease deaths 
into demographic and epidemiological components, in 23 selected countries, 2005-
2030.
Source: Abegunde DO, et al.18
Few LMICs have managed to comprehensively enumerate both the 
entire  population  distribution  and  all  deaths  occurring  in  the  entire 
population in order to monitor the age-standardized CVD mortality rates 
over time. In the Seychelles (an upper middle income small island state in 
the African  region),  where  these  figures  have  been  available,  the  age 402 PublicHealthReviews,Vol.33,No2
adjusted mortality from stroke, myocardial infarction and all CVD has 
decreased by as much as 40 percent between 1989 and 2010,19 consistent 
with vigorous prevention programs and policy (e.g., comprehensive tobacco 
legislation) and universal free health care. This large decrease has succeeded 
in containing the total number of stroke deaths over time in spite of the 
largely increasing and aging population. Similar decreases in age-adjusted 
CVD mortality rates have been found in a few South American countries.20 
Although less favorable CVD trends may still prevail in a number of other 
LMICs, findings of a decline in age-adjusted rates of CVD in some LMICs 
suggest that the anticipated increase in the CVD burden can be curbed, and 
eventually reversed, when considering the large potential for scaling up 
cost-effective  interventions  for  the  prevention  and  control  of  NCDs  in 
LMICs.
IMPACT ON INDIVIDUALS, HOUSEHOLDS, HEALTH SYSTEMS 
AND ECONOMY 
CVD and other chronic diseases are both a cause and a consequence of 
poverty,  as  illustrated  in  Figure  4.1,21  Poor  living  conditions  expose 
individuals to an environment that is not conducive to healthy lifestyles and 
augments the risk of NCDs. In poor areas, shops tend to sell more energy-
dense foods, alcohol and cigarettes than fruit and vegetables and there are 
fewer safe green areas needed to promote physical activity. Furthermore, 
public health programs to address NCDs are weak in these areas and access 
to adequate health services is limited. Inversely, CVD and chronic diseases 
contribute to poverty. The high expenses for long-term clinical management 
of  CVD  and  other  NCDs  are  a  frequent  cause  of  impoverishment, 
particularly in the many LMICs where most of the health care expenditures 
are  born  by  out-of-pocket  payments.22  This  has  major  collateral  con-
sequences at the household level,4 and it is now widely recognized that the 
rise of NCDs is a major barrier to social and economic development.23 This 
emphasizes  the  need  to  address  social  determinants  and  equity  issues, 
including universal access to basic health care for NCDs, when designing 
programs and health policy to reduce NCDs in LMICs.1,23
The cost of inaction in the area of NCDs in LMICs would be huge at a 
macroeconomic level. For every ten percent rise in mortality from NCDs, 
the yearly economic growth is estimated to be reduced by 0.5 percent.24 In 
China alone, it has been estimated that reducing CVD mortality by one 
percent per year over a 30-year period (2010-2040) could generate an 
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2010—more than USD $10.7 trillion at purchasing power parity.25 The 
yearly economic loss due to NCDs in China (approximately 50% of it is 
related to CVD) is approximately equivalent to four percent of the current 
annual output of LMICs.5 On a per-person basis, the annual economic 
losses are estimated to range between USD $25 in low income countries to 
USD $139 in upper middle income countries.5
Fig. 4. Relationship between NCDs and poverty. 
Source: Adapted from World Health Organization1
With regard to the response to this challenge, it is estimated that the 
annual  cost  per  capita  for  implementing  a  set  of  highly  cost-effective 
interventions could amount to only USD $1 for population-based measures 
aimed at reducing tobacco and harmful use of alcohol and to another ~USD 
$2 for the scaling up of multi-drug therapy for all persons at high CVD risk, 
as shown in Table 1.1,4 From a broader perspective, the World Economic 
Forum  ranks  NCDs  in  the  top  five  global  threats  to  global  economic 
development worldwide.26 These findings illustrate the mounting challenge 
of NCDs for national development in LMICs. Recent seminal economic 
documents on these issues provide timely information to advocate that 
higher priority should be given to the prevention and control of NCDs in 
LMICs.404 PublicHealthReviews,Vol.33,No2
Table 1
Estimatedyearlycostperhead(inUSD)ofapackage
forpreventionofcardiovasculardiseaseandothermainchronicdiseases
Brazil China India Mexico
South 
Africa
Tobacco  use-excise  tax  increase, 
information  and  labeling,  smoking 
restrictions and advertising bans
0.25 0.14 0.16 0.54 0.60
Harmful  alcohol  use-excise  tax 
increase,  advertising  bans,  restricted 
access
0.15 0.07 0.05 0.24 0.29
Unhealthy diet and physical activity-
mass  media  campaigns,  food  taxes 
and subsidies, nutritional information/
labeling,  and  marketing  restrictions 
(this analysis)
0.48 0.43 0.35 0.79 0.99
Reduced  dietary  salt  (mass  media 
campaigns,  regulation  of  the  food 
industry)
0.12 0.05 0.06 0.22 0.15
Combination  drug  therapy  for  high-
risk individuals
1.89 1.02 0.90 2.74 1.85
Total cost per head of intervention set 
(excluding  cost  synergies  or  future 
treatment cost savings)
2.89 1.72 1.52 4.53 3.88
Source: Cecchini M, et al.55
These issues are important considering that less than three percent of 
the official development assistance for health currently goes to NCDs while 
NCDs represent 62 percent of the global mortality in LMICs.27
DEBUNKING OLD MYTHS ABOUT CVD
Prioritizing CVD prevention and control in LMICs has been hampered by 
several  fallacious  but  tenacious  myths  for  decades  and  ten  widespread 
misunderstandings have been critically addressed in a key WHO report on 
NCDs.28 CVD has been considered a disease of the old age. However, 29 
percent of all CVD deaths occur among people under the age of 60 in 
LMICs, compared to 13 percent in high income countries.1,29 It has been CardiovascularDiseaseandGlobalPublicHealth 405
believed  that  CVD  mainly  affects  wealthy  people.  Yet,  CVD  dis-
proportionately affects the poor in most countries, including in LMICs.1,30 
Several major risk factors of CVD are more prevalent among the poor (e.g., 
tobacco, poor diet and obesity) and the poor also have less access to health 
services for management of NCDs. The relationship between NCD and 
poverty is discussed in more detail in a later paragraph. Another myth 
posits that CVD results from one’s own individual lifestyle choices and that 
there is no one to blame but those individuals who indulge in unhealthy 
behaviors. The truth is that personal responsibility can be fully effective 
only when individuals have equitable access to a healthy lifestyle and they 
are supported to make healthy choices. 
Another  myth  is  that  prevention  and  control  of  CVD  is  less  cost-
effective than prevention and control of infectious diseases. This belief may 
have arisen because CVD management in high income countries has largely 
relied on expensive clinical management at the individual level. However, 
several highly cost-effective interventions for the prevention and control of 
NCDs  have  been  well  documented-particularly  for  CVD  at  both  the 
individual and population levels,31,32 as discussed later. It has also been 
alleged that the scarce resources available for health should be exclusively 
allocated to the control of communicable diseases in LMICs. However 
most LMICs already experience a double burden of infectious diseases and 
chronic  diseases  and  NCDs  are  strongly  associated  with  poverty  and 
development.4,26,33-35  Furthermore,  prevention  and  control  of  NCDs  can 
markedly  improve  control  of  infectious  diseases  and  subsequently 
accelerate the achievement of millennium development goals related to 
infectious diseases.24
PREVENTION AS BOTH AN OPPORTUNITY AND A MUST 
Although a few community-based trials have been conducted successfully 
in high income countries,36 the conduct of such trials remain a challenge 
because interventions must target several risk factors simultaneously and 
include both population wide and individual-based interventions. Evidence 
must  therefore  also  build  on  other  data  sources  (e.g.,  cross-country 
comparison, quasi experiments and modeling data). For example, it was 
shown  that  CVD  mortality  could  decrease  by  up  to  20  percent  within 
months of implementation of a ban on smoking in enclosed public places37 
and CVD mortality fell largely and quickly following major changes in 
nutrition at the population level resulting from external circumstances.38,39406 PublicHealthReviews,Vol.33,No2
Intervention on four modifiable risk factors (tobacco use, poor diet, 
excess  alcohol  and  sedentary  habits)  has  the  potential  to  substantially 
reduce  the  burden  of  CVD,  diabetes,  cancers,  and  chronic  respiratory 
diseases.7,40 Evidence from high income countries suggests that favorable 
changes on these few main behaviors can explain 44-76 percent of the 
decline in coronary heart disease (CHD) mortality in Western countries 
while treatment explains approximately 23-47 percent.41 This “4 by 4” 
approach is central to the WHO Plan of Action for the Prevention and 
Control of NCDs.2
There are two main strategies for prevention of NCDs: the population 
wide  interventions  and  the  individual  based  interventions.  Among 
interventions targeting the entire population, structural measures aimed at 
making the healthy choice the easy choice for individuals are particularly 
attractive.  Importantly,  structural  interventions  may  not  need  explicit 
cooperation  of  individuals  in  order  to  produce  the  expected  lifestyles 
changes (e.g., improved diet through reformulation of manufactured foods 
to  reduce  trans  fats  or  salt).  Another  advantage  of  population-wide 
interventions is that they can be implemented at low cost and some of them 
can even generate revenue (e.g., taxes on tobacco and on alcohol). On the 
other hand, individual-level strategies often incur very high costs (e.g., 
lifelong treatment of hypertension or diabetes), which emphasizes the need 
to carefully select interventions (e.g., screening strategies, medications, 
etc.)  that  are  both  affordable  and  highly  cost-effective.  Selecting 
interventions based on cost-effectiveness criteria is also important to avoid 
that  the  provision  of  services  is  left  at  the  mercy  of  local  and  global 
commercial interests.
POPULATION-BASED INTERVENTIONS: THE NEED FOR MULTI-
SECTORAL ACTION 
To a large extent, abnormal behaviors in modern societies (e.g., overeating, 
excess salt intake, low physical activity, tobacco use) are “normal responses 
to abnormal environments”.42 Changes are unlikely to take place through 
individual information campaigns and interventions directed to patients at 
the health care level alone. Instead, a whole governmental approach is 
needed that involves all sectors, including national and local governments, 
industry  and  communities  (Figure  5).  For  example,  the  most  effective 
measures for tobacco control include increased taxes on tobacco products, 
bans on smoking in enclosed public places and on tobacco advertising, and 
compulsory health warnings on cigarette packets (Table 2). These measures CardiovascularDiseaseandGlobalPublicHealth 407
are prominent provisions of the WHO Framework Convention on Tobacco 
Control (FCTC), a legally binding treaty ratified by more than 175 countries. 
Similarly, improved diet will require reformulation of manufactured foods 
by the industry to lower the content of salt, saturated fats, trans fats, sugar 
and  calories  (Table  2).  Measures  to  promote  physical  activity  are  also 
needed, including well-lit and safe green areas and sidewalks and dedicated 
lanes for bikes and buses. All these measures imply the involvement of 
many sectors. Several countries have implemented comprehensive tobacco 
control policy43 and an increasing number are developing effective salt 
reduction  programs  (e.g.,  United  Kingdom,  Australia,  Finland,  Japan, 
South Africa, etc.).44 Multilevel programs to promote physical activity have 
been successful in several LMICS (e.g., “Agita São Paulo”* or “Ciclovía” 
in many countries4,45). Examples of ongoing comprehensive community 
based programs include many cities within the EPODE European Network** 
and the Foresight program*** to fight obesity in the United Kingdom.
Fig. 5. Comprehensive strategy to address cardiovascular disease. 
Source: Adapted from Institute of Medecine53
    * http://bit.ly/r4fJSu (Accessed 20 May, 2012)
  ** http://www.epode-european-network.com/ (Accessed 20 May, 2012)
*** http://www.bis.gov.uk/foresight (Accessed 20 May, 2012)408 PublicHealthReviews,Vol.33,No2
Table 2
“Bestbuy”interventionsforpreventionofcardiovasculardisease
andmajorchronicdiseases
Population based interventions addressing NCD risk factors
Tobacco use 
• Tax increases
• Smoke-free indoor workplaces and public places
• Health information and warnings about tobacco
• Bans on tobacco advertising, promotion and sponsorship
Harmful  alcohol 
use 
• Tax increases
• Restricted access to retailed alcohol
• Restrictions and bans on alcohol advertising and marketing
Unhealthy diet 
and physical 
inactivity 
•  Reduced  salt  intake  in  food  through  mass  media  campaigns  and 
reduced salt content in processed foods
• Replacement of trans fats with polyunsaturated fats
• Public awareness through mass media on diet and physical activity
Individual based interventions addressing NCDs in primary health care
CVD and 
diabetes 
• Multi-drug therapy for people who have had a heart attack or stroke or 
who are at a high risk (>30%) of CVD event in next 10 years
• Treatment of heart attacks with aspirin
Cancer 
• Hepatitis B immunization to prevent liver cancer (already scaled up)
• Screening and treatment of pre-cancerous lesions to prevent cervical 
cancer
Source: World Health Organization34
INDIVIDUAL LEVEL INTERVENTIONS: THE CASE FOR MULTI-
DRUG THERAPY 
Long-term care of asymptomatic conditions (e.g., hypertension, diabetes) 
is challenging. In a study in Dar es Salam (Tanzania), less than one third of 
persons identified to have hypertension during a screening performed at 
their homes attended a health center after having been advised to do so and 
less than three percent were taking an antihypertensive treatment 12 months 
later.46 In Seychelles, less than 30 percent of newly hypertensive patients 
regularly took their antihypertensive medication after one year of treatment, 
despite free health care.47 Heath systems need therefore to be strengthened 
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primary health care level. A number of issues need be addressed at all levels 
of  the  six  building  blocks  of  heath  systems48  including  integration  of 
essential care for NCD at the primary care level (e.g., “whole patient” 
approach  rather  than  competing  vertical  programs),  moving  toward 
universal coverage to reduce out-of-pocket payment by patients, improved 
efficiency,  formulation  of  simple  guidelines,  adequate  training,  task 
shifting, etc. The use of a combination of several off-license medications 
has been advocated4,5,7,18,34 and this is a “best buy” intervention for CVD 
prevention at the individual level (Table 2). This strategy (e.g., “polypill”) 
may have several advantages over the usual “single risk factor” approaches 
including improved adherence, lower cost, simplified treatment schedules, 
and partial task shifting from doctors to nurses.49,50 Around five to ten 
percent of all adults aged 35-64 years would need to be treated51 at a cost of 
USD $1-2 per capita per year (around USD $12 billion per year in all 
LMICs). Table 1 is a reminder that despite being particularly cost-effective, 
individual-level risk reduction strategies tend to incur high total cost as 
compared to other “best buy” population wide interventions.34
PRIORITY INTERVENTIONS FOR LMICs - BEST BUYS 
Compelling evidence on effective interventions for the prevention of NCDs 
at  both  the  population  and  individual  levels  has  become  available 
recently.1,7,52-54 Those interventions that are also feasible, affordable, and 
scalable at the entire population level have been labeled “best buys” by the 
WHO and are listed in Table 2.1,5,7,34
Affordability is essential when considering that total annual expenditures 
for health care range from more than USD $5000 in several high income 
countries to less than USD $50 per capita in many low income countries. In 
LMICs, it has been estimated that two population-wide interventions (a 
15%  reduction  of  salt  intake  and  the  implementation  of  the  four  key 
provisions  of  the  Framework  Convention  on  Tobacco  Control)  could 
prevent 14 million premature deaths over ten years. As shown in Table 1, 
these interventions could be implemented for less than USD $0.40 per 
person per year in LMICs.18 A few other interventions (“good buys”) could 
deliver substantial additional health gains (e.g., communication strategies 
to improve awareness about the benefits of healthy eating and physical 
activity,  fiscal  measures  that  increase  the  price  of  unhealthy  food  and 
reduce of cost of healthy foods, and regulatory measures that improve 
nutritional  information  or  restrict  the  marketing  of  unhealthy  foods  to 
children1,55).410 PublicHealthReviews,Vol.33,No2
With  regards  to  implementation,  clear  goals,  targets  and  indicators 
alongside with a plan of action should be set at the national level to spearhead 
a timely and coordinated response and elicit appropriate resources.7,56 A 
high  level  multi-sector  committee  is  needed  to  oversee  the  effective 
implementation of interventions in many sectors (i.e., beyond the health 
sector). Strong leadership from the health sector is needed to champion 
policy tradeoffs that favor health over political and commercial interests, 
particularly  for  interventions  that  fall  under  other  sectors.  Successful 
intersectoral  action  requires  focused  leadership,  effective  partnerships, 
transparent accountability, research, monitoring and evaluation.2,7
THE POLITICAL DECLARATION OF THE UNITED NATIONS 
HIGH LEVEL MEETING ON NCDs: A NEW OPPORTUNITY TO 
MOVE THE NCD AGENDA FORWARD
A milestone for the global response to NCDs was achieved in New York on 
19-20 September 2011 with the adoption of the Political Declaration of the 
High Level Meeting (HLM) on the Prevention and Control of NCDs.57,58 
This historical event opened up new opportunities to move the NCD agenda 
forward.56 Because a number of high level meetings in all regions took 
place before the HLM and equally important meetings will follow to ensure 
implementation, the “power of the process” of this event has generated an 
unprecedented interest for NCDs and was instrumental in making NCDs 
appear on the radar of policy makers in LMICs. Several seminal reports 
were produced for this occasion4,5,7,25,33,34 to advocate the need to address 
NCDs in LMICs and to synthesize the main challenges and opportunities 
related to NCD prevention along both the health and development agendas.
The political declaration offers affirmation, empowerment, coordination, 
and continuity for NCD prevention and control nationally and globally.59 
Examples  of  provisions  include  that  the  consumption  of  tobacco  and 
alcohol  will  be  curtailed  through  national  taxation  and  marketing 
restrictions; the use of saturated fats, trans fats, salt, and sugar will be 
constrained  through  regulation  and  negotiation;  public  campaigns  will 
target the four modifiable risk factors (tobacco use, unhealthy diet, physical 
inactivity, harmful use of alcohol) and their attendant disease groups; the 
WHO, the designated coordinator of the global response to the NCDs, will 
develop  a  comprehensive  global  monitoring  framework;  and  the  UN 
Secretary  General  will  consider  relevant  partnerships,  monitor  the 
realization of HLM commitments, and report on progress in the prevention 
and control of NCDs.59CardiovascularDiseaseandGlobalPublicHealth 411
CONCLUSIONS
It is now well recognized that the emergence of CVD and other NCDs in 
LMICs is a major global public health challenge. The increasing burden of 
NCDs  worldwide  is  largely  attributable  to  the  demographic  transition, 
which causes a large increase in the numbers of the middle-aged and older 
people who are at increased risk of NCDs.
The good news is that we now know of a number of effective strategies 
to prevent CVD and NCDs. Interventions to reduce four common behavioral 
risk factors (tobacco use, unhealthy diet, low physical activity and excess 
consumption of alcohol) are at the core of effective primary prevention of 
the main NCDs at the population level. These behaviors are best improved 
primarily  through  structural  interventions  (e.g.,  taxes  on  unhealthy 
products, reformulation of manufactured food, shaping urban environments 
to  encourage  physical  activity).  In  addition,  health  systems  in  LMICs 
should  be  reoriented  to  deliver  appropriate  management  to  high  risk 
individuals  with  emphasis  on  efficient  and  integrated  supply  of  cost-
effective treatment at the primary health care level.
Several interventions at both the population and individual levels are 
cost-effective  and  those  that  are  feasible,  affordable  and  scalable  are 
regarded  as  “best  buys”.  The  full  implementation  of  these  “best  buy” 
interventions might be the necessary and sufficient ingredients for curbing 
NCDs in LMICs. The Political Declaration of the United Nations High 
Level  Meeting  on  NCDs  and  a  number  of  recent  reports  from  health, 
economic and development organizations highlight the need to implement 
these “best buy” interventions with high priority, which provides a new 
opportunity to move the NCD agenda forward in LMICs.
Acronyms list:
CVD = Cardiovascular Disease
GNI = Gross national income
HLM = United Nations High Level Meeting on the Prevention and Control of 
NCDs
LMICs = Low and middle income countries
NCD = Noncommunicable disease
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